Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Axcella Therapeutics

Axcella Announces Reverse Stock Split Effective September 19, 2023
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Granted Patent for Long COVID Fatigue Treatment
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Reports Second Quarter Financial Results and Provides Business Update
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Reports First Quarter Financial Results and Provides Business Update
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Announces Program Reprioritization and Corporate Restructuring
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Reports Third Quarter Financial Results and Provides Business Update
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Reports Second Quarter Financial Results and Provides Business Update
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Reports First Quarter Financial Results and Provides Business Update
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics Details Clinical and Operational Milestones for 2022
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference
From Axcella Therapeutics
Via Business Wire
Tickers AXLA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.